Magnesium%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520sulphate

# Magnesium Sulfate ## Overview Magnesium sulfate is an essential mineral that plays a vital role in numerous biochemical functions, including nerve impulse transmission, muscle contraction, and cardiac function. It is available in intravenous (IV) and intramuscular (IM) formulations. ## Primary Indications * **Eclampsia and Preeclampsia:** Treatment and prevention of seizures in pregnant women. * **Hypomagnesemia:** Treatment of magnesium deficiency. * **Torsades de Pointes:** Management of this specific type of polymorphic ventricular tachycardia. * **Bronchospasm:** Adjunctive therapy in severe acute asthma or COPD exacerbations, particularly in patients unresponsive to standard bronchodilators. ## Adult Dosing * **Eclampsia Prophylaxis/Treatment:** * Loading dose: 4-6 grams IV over 15-20 minutes, followed by a maintenance infusion of 1-2 grams per hour. Alternatively, 4 grams IM (2 grams in each buttock) followed by 5 grams IM every 4 hours as needed. * **Hypomagnesemia:** * Severe deficiency: 4-5 grams (approximately 32-40 mEq) IV infusion over 4 hours or as a continuous infusion. May be followed by further doses of 1-2 grams (8-16 mEq) IV every 12-24 hours depending on serum magnesium levels. * Less severe: 1 gram (8 mEq) IM every 6-8 hours for 3-4 doses. * **Torsades de Pointes:** * 2-4 grams (16-32 mEq) IV bolus over 5-10 minutes, followed by a continuous infusion of 1-2 grams per hour. * **Bronchospasm:** * 1-2 grams (8-16 mEq) IV infusion over 15-20 minutes. Dosing for specific indications may vary based on institutional protocols. ## Pediatric Dosing Dosing in pediatric patients is less standardized and often requires careful calculation based on weight and clinical indication. * **Hypomagnesemia:** * 10-20 mg/kg/dose (0.1-0.2 mEq/kg/dose) IV over 3-6 hours. Maximum dose not to exceed 1 gram (8 mEq). May be repeated every 4-12 hours. * **Eclampsia (less common):** Dosing is typically based on adult protocols with adjustments for weight, but specific pediatric guidelines are not universally established and should be guided by expert consultation. ## Dose Adjustments * **Renal Impairment:** Magnesium sulfate is renally excreted. In patients with significant renal impairment, doses should be reduced, and serum magnesium levels should be closely monitored to avoid accumulation and hypermagnesemia. A typical reduction might be 50% for moderate renal impairment and further reduction with severe impairment, but specific guidelines are limited. ## Contraindications * Myocardial damage. * Heart block. * Hypermagnesemia. * Hyperkalemia (caution with IV administration). * Severe renal impairment (caution and dose adjustment). * Hypocalcemia (magnesium administration can worsen hypocalcemia). ## Adverse Effects * **Common:** Flushing, warmth, sweating, hypotension, nausea, vomiting, decreased reflexes, drowsiness. * **Serious:** Respiratory depression, cardiac arrest, hypocalcemia, hypermagnesemia (symptoms include absent deep tendon reflexes, somnolence, confusion, muscle weakness, decreased blood pressure, bradycardia, arrhythmias, cardiac arrest). ## Key Drug Interactions * **Neuromuscular Blockers (e.g., rocuronium, succinylcholine):** Magnesium sulfate can potentiate neuromuscular blockade, potentially leading to prolonged muscle paralysis and respiratory depression. * **Calcium Channel Blockers:** Additive hypotensive effects. * **Digitalis Glycosides:** Increased risk of digitalis toxicity, especially in hypokalemia and hypomagnesemia. * **Tetracyclines and Quinolones:** Magnesium sulfate can reduce the absorption of oral tetracyclines and fluoroquinolones; administer these agents at least 2 hours before or 4-6 hours after magnesium sulfate. ## Monitoring * **Serum Magnesium Levels:** Essential, especially in patients with renal impairment or receiving prolonged infusions. Target levels vary by indication but are typically between 4-7 mEq/L for eclampsia and hypomagnesemia treatment. * **Renal Function:** Monitor creatinine and BUN, particularly with dose adjustments. * **Vital Signs:** Blood pressure, heart rate, respiratory rate. * **Deep Tendon Reflexes:** Loss of reflexes is an early sign of hypermagnesemia. * **Urine Output:** Adequate urine output is necessary for magnesium excretion. * **ECG:** May be warranted in patients receiving high doses or with cardiac concerns. ## Clinical Pearls * Magnesium sulfate is an effective anticonvulsant, tocolytic, and antiarrhythmic agent. * Always check the concentration of magnesium sulfate solutions, as it is available in various strengths (e.g., 10%, 12.5%, 50%). * IV administration should be slow and controlled to minimize hypotension and flushing. * For IV administration, use an infusion pump. * Monitor closely for signs and symptoms of hypermagnesemia, especially in patients with impaired renal function. * Calcium gluconate is the antidote for severe hypermagnesemia and should be readily available. *** **Disclaimer:** This information is intended for clinical use by healthcare professionals. It is not exhaustive and does not replace professional medical judgment. Always consult the most current prescribing information, institutional guidelines, and expert resources for definitive patient care decisions.